文献速递间质性肺疾病

催眠药与特发性肺纤维化患者死亡率:医院与国家数据库分析

Hypnotics and Mortality in Idiopathic Pulmonary Fibrosis: Hospital and National Data-Based Analysis.
PubMed 文献 · Chest · 2024-11-05

本研究基于两个日本医院IPF队列(99例和123例)及日本全国医保数据库IPF队列(30,218例),采用时依Cox模型和模拟目标试验分析催眠药使用与死亡率的关系。结果显示,持续使用催眠药与全因死亡风险升高相关,医院队列中还与疾病进展相关。鉴于IPF患者中新使用催眠药的3年累积发生率较高(13.4%–24.1%),需重新评估其合理使用。

要点

  • 持续使用催眠药与IPF患者全因死亡风险升高相关。
  • 医院队列中持续使用催眠药还与疾病进展风险升高相关。
  • IPF诊断后3年内新使用催眠药的累积发生率为13.4%–24.1%。

核心结论

  • 持续使用催眠药与IPF患者全因死亡风险升高相关。
  • 鉴于催眠药使用累积发生率较高,需重新评估IPF患者催眠药的合理使用。

研究设计与样本

  • 研究纳入两个日本医院IPF队列(99例和123例)及日本全国医保数据库IPF队列(30,218例)。
  • 采用多变量Cox模型(时依协变量)和模拟目标试验(新使用者设计)分析催眠药使用与结局的关联。

主要发现

  • 两个医院队列中,持续使用催眠药与全因死亡风险升高及疾病进展相关。
  • 全国数据库队列中,持续使用催眠药与全因死亡风险升高相关。
  • 亚组分析显示,除某些亚群外,持续使用催眠药与死亡率升高的关联不受性别和合并症影响。
  • IPF诊断后3年内新使用催眠药的累积发生率为13.4%至24.1%。

临床怎么用

  • 对IPF患者应审慎评估催眠药的使用指征,并关注其潜在死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with idiopathic pulmonary fibrosis (IPF) may experience insomnia and use hypnotics. However, the effect of the use of hypnotics on their clinical course remains unclear. RESEARCH QUESTION: Is the use of hypnotics associated with an increased risk of mortality in patients with IPF? STUDY DESIGN AND METHODS: This study included 99 patients with IPF from the Hamamatsu hospital-based cohort and 123 patients with IPF from the Seirei hospital-based cohort, as well as 30,218 patients with IPF from the National Database of Health Insurance Claims and Specific Health Checkups of Japan (the NDB cohort). To analyze the association of hypnotics use with outcomes avoiding immortal time bias, multivariable Cox models with time-dependent covariates and target trial emulation with a new user design were used for the hospital- and NDB-based cohorts. RESULTS: In the cohorts studied, the 3-year cumulative incidence of new use of hypnotics following the IPF diagnosis ranged from 13.4% to 24.1%. In both hospital-based cohorts, the continuous use of hypnotics was associated with an increased risk of all-cause mortality and disease progression. In the NDB cohort, the continuous use of hypnotics was also associated with an increased risk of all-cause mortality. Subgroup analysis found associations between the continuous use of hypnotics and increased mortality regardless of sex and comorbidities, excluding certain subpopulations. INTERPRETATION: This study found that continuous use of hypnotics was associated with an increased risk of mortality in patients with IPF. Given the relatively high cumulative incidence of hypnotics use in this population, there is an urgent need to reassess the appropriate use of hypnotics for patients with IPF.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Hozumi H, Endo Y, Kono M, et al. Hypnotics and Mortality in Idiopathic Pulmonary Fibrosis: Hospital and National Data-Based Analysis. Chest. 2024. PMID: 39510406. doi:10.1016/j.chest.2024.10.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。